|
DUSP12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.19660014808699E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.87120002720565E-09 |
| Normal-vs-Stage2 |
1.018780E-04 |
| Normal-vs-Stage3 |
2.06960000026513E-07 |
| Normal-vs-Stage4 |
3.83560000000172E-05 |
| Stage1-vs-Stage2 |
8.473000E-01 |
| Stage1-vs-Stage3 |
9.053400E-01 |
| Stage1-vs-Stage4 |
8.785200E-01 |
| Stage2-vs-Stage3 |
9.264600E-01 |
| Stage2-vs-Stage4 |
9.731600E-01 |
| Stage3-vs-Stage4 |
9.559800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.0102002808502E-10 |
| Normal-vs-AfricanAmerican |
2.083500E-03 |
| Normal-vs-Asian |
2.173600E-04 |
| Caucasian-vs-AfricanAmerican |
3.878600E-01 |
| Caucasian-vs-Asian |
2.744800E-01 |
| AfricanAmerican-vs-Asian |
9.616000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.38249999956675E-07 |
| Normal-vs-Female |
8.70429950339258E-10 |
| Male-vs-Female |
6.014000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.71980005184247E-09 |
| Normal-vs-Age(41-60Yrs) |
3.89599996708512E-09 |
| Normal-vs-Age(61-80Yrs) |
6.44890000000009E-05 |
| Normal-vs-Age(81-100Yrs) |
6.679600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.042800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.949000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.487800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.160000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.935200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.924800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.038800E-03 |
| Classical-VS-Follicular |
4.500400E-01 |
| Classical-VS-Other |
5.690200E-01 |
| Classical-VS-Normal |
5.43279999987156E-07 |
| Tall-VS-Follicular |
1.355970E-01 |
| Tall-VS-Other |
9.009800E-01 |
| Tall-VS-Normal |
4.17320000778432E-09 |
| Follicular-VS-Other |
6.800400E-01 |
| Follicular-VS-Normal |
2.33859999999586E-05 |
| Other-VS-Normal |
1.147230E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50180000552314E-08 |
| Normal-vs-N1 |
3.11860000046238E-08 |
| N0-vs-N1 |
7.783700E-02 |
|
|
